QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, May 14, 2008, 28(20):5149-5158; doi:10.1523/JNEUROSCI.4878-07.2008

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Sturchler, E. Articles by Heizmann, C. W. Search for Related Content PubMed PubMed Citation Articles by Sturchler, E. Articles by Heizmann, C. W.

 Previous Article  |  Next Article 

Neurobiology of Disease
Site-Specific Blockade of RAGE-V_d Prevents Amyloid-β Oligomer Neurotoxicity

Emmanuel Sturchler,¹ Arnaud Galichet,¹ Mirjam Weibel,¹ Estelle Leclerc,² and Claus W. Heizmann¹

¹Department of Pediatrics, Division of Clinical Chemistry and Biochemistry, University of Zurich, 8032 Zurich, Switzerland, and ²Department of Chemistry and Biochemistry, Florida Atlantic University, Boca Raton, Florida 33431

Correspondence should be addressed to Dr. Claus W. Heizmann, Department of Pediatrics, Division of Clinical Chemistry and Biochemistry, University of Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland. Email: claus.heizmann{at}kispi.uzh.ch

In the genesis of Alzheimer's disease (AD), converging lines of evidence suggest that amyloid-β peptide (Aβ) triggers a pathogenic cascade leading to neuronal loss. It was long assumed that Aβ had to be assembled into extracellular amyloid fibrils or aggregates to exert its cytotoxic effects. Over the past decade, characterization of soluble oligomeric Aβ species in the brains of AD patients and in transgenic models has raised the possibility that different conformations of Aβ may contribute to AD pathology via different mechanisms. The receptor for advanced glycation end products (RAGE), a member of the Ig superfamily, is a cellular binding site for Aβ. Here, we investigate the role of RAGE in apoptosis induced by distinct well characterized Aβ conformations: Aβ oligomers (AβOs), Aβ fibrils (AβFs), and Aβ aggregates (AβAs). In our in vitro system, treatment with polyclonal anti-RAGE antibodies significantly improves SHSY-5Y cell and neuronal survival exposed to either AβOs or AβAs but does not affect AβF toxicity. Interestingly, using site-specific antibodies, we demonstrate that targeting of the V_d domain of RAGE attenuates AβO-induced toxicity in both SHSY-5Y cells and rat cortical neurons, whereas inhibition of AβA-induced apoptosis requires the neutralization of the C_1d domain of the receptor. Thus, our data indicate that distinct regions of RAGE are involved in Aβ-induced cellular and neuronal toxicity with respect to the Aβ aggregation state, and they suggest the blockage of particular sites of the receptor as a potential therapeutic strategy to attenuate neuronal death.

Key words: Alzheimer's disease; amyloid-β; RAGE; Ig-like domains; cortical neurons; apoptosis

---

Received June 26, 2007; revised March 12, 2008; accepted March 31, 2008.

Correspondence should be addressed to Dr. Claus W. Heizmann, Department of Pediatrics, Division of Clinical Chemistry and Biochemistry, University of Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland. Email: claus.heizmann{at}kispi.uzh.ch

This article has been cited by other articles:

				M. Li, D.-S. Shang, W.-D. Zhao, L. Tian, B. Li, W.-G. Fang, L. Zhu, S.-M. Man, and Y.-H. Chen Amyloid {beta} Interaction with Receptor for Advanced Glycation End Products Up-Regulates Brain Endothelial CCR5 Expression and Promotes T Cells Crossing the Blood-Brain Barrier J. Immunol., May 1, 2009; 182(9): 5778 - 5788. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help